Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.
Adult
Aged
Drug Prescriptions
Drug Utilization
/ trends
Female
France
/ epidemiology
Gabapentin
/ administration & dosage
Humans
Incidence
Male
Middle Aged
Practice Patterns, Physicians'
/ trends
Pregabalin
/ administration & dosage
Prescription Drug Misuse
/ trends
Retrospective Studies
Risk Assessment
Risk Factors
Substance-Related Disorders
/ epidemiology
abuse
addiction
gabapentin
misuse
pregabalin
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
04
06
2018
revised:
06
01
2019
accepted:
01
02
2019
pubmed:
10
2
2019
medline:
14
4
2020
entrez:
10
2
2019
Statut:
ppublish
Résumé
The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population. New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse. Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (P < 0.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29-1.69]), age (HR In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.
Identifiants
pubmed: 30737829
doi: 10.1111/bcp.13892
pmc: PMC6533441
doi:
Substances chimiques
Pregabalin
55JG375S6M
Gabapentin
6CW7F3G59X
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1269Informations de copyright
© 2019 The British Pharmacological Society.
Références
CNS Neurosci Ther. 2010 Spring;16(1):45-50
pubmed: 20070788
Drug Alcohol Depend. 2012 Nov 1;126(1-2):13-20
pubmed: 22475815
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Eur J Clin Pharmacol. 2011 Mar;67(3):319-20
pubmed: 20972557
Therapie. 2016 Dec;71(6):575-578
pubmed: 27473599
Fundam Clin Pharmacol. 2016 Dec;30(6):616-624
pubmed: 27351637
Eur Addict Res. 2014;20(3):115-8
pubmed: 24192603
CNS Drugs. 2016 Jan;30(1):9-25
pubmed: 26767525
Fundam Clin Pharmacol. 2012 Aug;26(4):549-56
pubmed: 21564282
BMJ. 2018 Mar 20;360:k959
pubmed: 29559429
BMC Pharmacol Toxicol. 2013 Jun 13;14:30
pubmed: 23763896
Addiction. 2016 Oct;111(10):1699-700
pubmed: 27454743
Am J Psychiatry. 2014 Jun;171(6):691
pubmed: 24880512
Drugs. 2017 Mar;77(4):403-426
pubmed: 28144823
Rev Med Interne. 2015 Jun;36(6):411-7
pubmed: 25547954
J Pain. 2018 Oct;19(10):1104-1112
pubmed: 29678564
Clin Drug Investig. 2016 Sep;36(9):735-742
pubmed: 27300651
Addiction. 2010 Feb;105(2):288-99
pubmed: 20078487
Fundam Clin Pharmacol. 2011 Oct;25(5):633-41
pubmed: 21077937
Epilepsia. 2011 Apr;52(4):826-36
pubmed: 21320112
Psychiatr Q. 2016 Dec;87(4):763-767
pubmed: 26887855
Am J Addict. 2015 Mar;24(2):173-177
pubmed: 25864607
Ir Med J. 2015 Nov-Dec;108(10):309-10
pubmed: 26817289
Drug Alcohol Depend. 2017 May 1;174:58-64
pubmed: 28315808
Eur J Clin Pharmacol. 2010 Sep;66(9):947-53
pubmed: 20563568
Pain. 2013 Nov;154(11):2287-96
pubmed: 23792283
J Addict Med. 2013 Mar-Apr;7(2):147-9
pubmed: 23519046
Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16
pubmed: 29055037
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1083-1086
pubmed: 28493425
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Drug Saf. 2013 Jan;36(1):55-62
pubmed: 23315296
PLoS Med. 2017 Oct 3;14(10):e1002396
pubmed: 28972983
Basic Clin Pharmacol Toxicol. 2010 Nov;107(5):883-6
pubmed: 22545971
CNS Drugs. 2010 Jul;24(7):611-20
pubmed: 20527997
Pharmacopsychiatry. 2016 Jul;49(4):155-61
pubmed: 26951495
Psychother Psychosom. 2011;80(2):118-22
pubmed: 21212719
Br J Pharmacol. 2017 Dec;174 Suppl 1:S130-S159
pubmed: 29055038
Br J Clin Pharmacol. 2019 Jun;85(6):1260-1269
pubmed: 30737829
Rev Epidemiol Sante Publique. 2010 Aug;58(4):286-90
pubmed: 20598822
Pain Physician. 2013 Jan;16(1):89-100
pubmed: 23340537
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):162-169
pubmed: 27807907
CNS Drugs. 2014 Jun;28(6):491-6
pubmed: 24760436
Br J Gen Pract. 2012 Aug;62(601):406-7
pubmed: 22867659
Eur Neuropsychopharmacol. 2015 Oct;25(10):1566-77
pubmed: 26256008
Eur J Clin Pharmacol. 2014 Feb;70(2):197-204
pubmed: 24141597
Br J Clin Pharmacol. 2014 Jul;78(1):190-1
pubmed: 25083536
BMC Public Health. 2015 Mar 25;15:288
pubmed: 25885781
J R Coll Physicians Edinb. 2017 Dec;47(4):310-313
pubmed: 29537399
Therapie. 2015 Mar-Apr;70(2):147-65
pubmed: 25858571
Drug Alcohol Depend. 2018 Jun 1;187:88-94
pubmed: 29649695
Addiction. 2016 Jul;111(7):1160-74
pubmed: 27265421
Addiction. 2017 Sep;112(9):1580-1589
pubmed: 28493329
CNS Drugs. 2016 Jul;30(7):647-54
pubmed: 27312320
Cochrane Database Syst Rev. 2013 Nov 11;(11):CD010567
pubmed: 24217986
Eur J Clin Pharmacol. 2013 Dec;69(12):2021-5
pubmed: 23989299